GRAVITAS: Gauging Responsiveness With A VerifyNow Assay-Impact On Thrombosis And Safety (GRAVITAS)

Clinical Trial ID NCT00645918

PubWeight™ 18.16^‹?›

🔗 Visit the ClinicalTrials.gov page for NCT00645918

Top papers

Rank	Title	Journal	Year	PubWeight™‹?›
1	Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.	JAMA	2011	6.39
2	Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the Gauging Responsiveness with a VerifyNow P2Y12 assay: Impact on Thrombosis and Safety (GRAVITAS) trial.	Circulation	2011	2.98
3	Antiplatelet therapies for the treatment of cardiovascular disease.	Nat Rev Drug Discov	2010	1.66
4	Evaluation of individualized clopidogrel therapy after drug-eluting stent implantation in patients with high residual platelet reactivity: design and rationale of the GRAVITAS trial.	Am Heart J	2009	1.03
5	Aspirin and clopidogrel hyporesponsiveness and nonresponsiveness in patients with coronary artery stenting.	Vasc Health Risk Manag	2009	0.90
6	Antiplatelet therapy: Personalized medicine for clopidogrel resistance?	Nat Rev Cardiol	2009	0.87
7	Variability in response to clopidogrel: how important are pharmacogenetics and drug interactions?	Br J Clin Pharmacol	2011	0.87
8	Considerable variability in platelet activity among patients with coronary artery disease in response to an increased maintenance dose of clopidogrel.	Coron Artery Dis	2009	0.86
9	Antiplatelet therapy in acute coronary syndromes: focus on ticagrelor.	J Blood Med	2010	0.85
10	Antiplatelet resistance in stroke.	Expert Rev Neurother	2011	0.85
11	Genetic regulation of platelet receptor expression and function: application in clinical practice and drug development.	Arterioscler Thromb Vasc Biol	2010	0.78
12	Platelet function analysis: at the edge of meaning.	Thromb Haemost	2009	0.75